Cargando…

P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Detalles Bibliográficos
Autores principales:	Fathi, Amir, Wang, Eunice, Issa, Ghayas, Altman, Jessica, Montesinos, Pau, de Botton, Stéphane, Walter, Roland, Pettit, Kirsten, Patnaik, Mrinal, Kremyanskaya, Marina, Baer, Maria, M Foran, James, Schiller, Gary, Ades, Lionel, Heiblig, Maël, Peterlin, Pierre, Salamero Garcia, Olga, Papayannidis, Cristina, Nie, Kun, Ahsan Mackey, Julie, Tabachri, Marilyn, Corum, Daniel, Leoni, Mollie, Dale, Stephen, Erba, Harry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429668/ http://dx.doi.org/10.1097/01.HS9.0000968924.19161.da

Ejemplares similares

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Zeidan, Amer M, et al.
Publicado: (2023)

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1
por: Fiskus, Warren, et al.
Publicado: (2022)

Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax
por: Rausch, Johanna, et al.
Publicado: (2023)

PB1761: PRECLINICAL EVALUATION OF THE MENIN INHIBITOR ZIFTOMENIB IN PRIMARY AML SPECIMENS
por: Stevens, Brett, et al.
Publicado: (2023)

Acute Promyelocytic Leukemia
por: Thomas, Xavier, et al.
Publicado: (2020)

504 absolutely essential words
por: Bromberg, Murray, et al.
Publicado: (2012)

The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively
por: Heiblig, Maël, et al.
Publicado: (2021)

504: Subsidiary sources of heavy quarks at LEP
por: Colas, P
Publicado: (1998)

PATCHY reference manual: version 5.04
por: Zoll, Julius
Publicado: (1995)

Machine development du 50.4-1970
por: Henny, L, et al.
Publicado: (1970)

SUN-504 A Case of T3 Thyrotoxicosis
por: Peloquin, Isabelle Daneault, et al.
Publicado: (2020)

Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis
por: McDuff, Fiona Kate Elizabeth, et al.
Publicado: (2011)

Schizophrenia interactome with 504 novel protein–protein interactions
por: Ganapathiraju, Madhavi K, et al.
Publicado: (2016)

SAT-504 Delayed Hypersensitivity to Levothyroxine, and Oral Desensitization
por: Sandooja, Rashi, et al.
Publicado: (2020)

PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY
por: Raffoux, E., et al.
Publicado: (2022)

Spectrum of perforation peritonitis in India-review of 504 consecutive cases
por: Jhobta, Rajender Singh, et al.
Publicado: (2006)

An integrated map of structural variation in 2,504 human genomes
por: Sudmant, Peter H., et al.
Publicado: (2015)

Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis
por: Melchers, R.C., et al.
Publicado: (2019)

Origin and Spread of the ALDH2 Glu504Lys Allele
por: Zhang, Xiaokai, et al.
Publicado: (2021)

Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML
por: Duchmann, Matthieu, et al.
Publicado: (2022)

Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database
por: Antherieu, Gabriel, et al.
Publicado: (2023)

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1
por: Oñate, Guadalupe, et al.
Publicado: (2022)

Function of homo- and hetero-oligomers of human nucleoplasmin/nucleophosmin family proteins NPM1, NPM2 and NPM3 during sperm chromatin remodeling
por: Okuwaki, Mitsuru, et al.
Publicado: (2012)

NPM and NPM-MLF1 interact with chromatin remodeling complexes and influence their recruitment to specific genes
por: Darracq, Anaïs, et al.
Publicado: (2019)

How to Transform an Exceptional Case Report Into a Therapy: Following the Frog Out of the Box
por: Heiblig, Maël, et al.
Publicado: (2021)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

Wolfgang Amadeus Mozart Symphoy 38 in D K 504 Prague/
por: Gardiner, John Eliot

Effects of TONS504-photodynamic therapy on mouse mammary tumor cells
por: Osaki, Tomohiro, et al.
Publicado: (2018)

P1135: EFFECT OF GLUCARPIDASE RESCUE IN PATIENTS WITH HIGH-DOSE METHOTREXATE INDUCED ACUTE KIDNEY INJURY: A FRENCH PHARMACOVIGILANCE DATABASE STUDY
por: Pierre, Sabrina, et al.
Publicado: (2023)

PB1865: NPM1-MUT MONITORING DURING GILTERITINIB TREATMENT IDENTIFIES DIFFERENT DYNAMICAL PATTERNS IN RESPONSIVE PATIENTS
por: Sartor, Chiara, et al.
Publicado: (2023)

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
por: Issa, Ghayas C., et al.
Publicado: (2023)

Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML
por: Diaz de la Guardia, Rafael, et al.
Publicado: (2020)

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
por: Singh, Vijay Kumar, et al.
Publicado: (2019)

Seminal profile of 23,504 patients over the years: 7 years of experience
por: Nogueira, Camila, et al.
Publicado: (2018)

SAT-504 Role of Genetic Screening for FHH in a Patient with Hypercalcemia and Hyperparathyroidism
por: Caldwell, Laura, et al.
Publicado: (2019)

504 A Model for Introducing Biomedical Commercialization and Entrepreneurship Concepts to Research Faculty
por: Cook, Samantha, et al.
Publicado: (2022)

FRI504 Ectopic Hyperactive Mediastinal Thyroid Tissue: A Case Report
por: Dimech, Christina, et al.
Publicado: (2023)

Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia
por: Chen, Yingyu, et al.
Publicado: (2020)

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
por: Fiskus, Warren, et al.
Publicado: (2022)

Role of aldehyde dehydrogenase 2 Glu504lys polymorphism in acute coronary syndrome
por: Xu, Feng, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_p8506eetiojn40psdqlvp6ttu4